Results 1 - 20 of 167 in Keryx Biopharmaceuticals
Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
Growing Stock Report expands its Biotech Gainers Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
... recent examples of the high levels of volatility that small cap biotech investing can throw at you. Keryx Biopharmaceuticals ( KERX ) is an early stage biotech company that had been focusing on developing a treatment for kidney disease, called ... Comment?
The online StockConsultant latest screen has found a biotech company that provides drugs for the treatment of cancer and renal diseases Keryx Biopharmaceuticals stock under a breakout watch above 8.77. KERX stock price is up 5.6% to 8.68 on 50.3% higher volume and is trying to break over double resistance. Comment?
Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call. At this time, all participants are in a listen-only mode. Comment?
... holding the shares of Sarepta Therapeutics ( SRPT ), which we reviewed unfavorably on April 24th . Keryx Biopharmaceuticals is developmental stage biopharmaceutical company that's focused on the acquisition, development and commercialization of ... Comment?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK, May 6, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. Comment?
Keryx Biopharmaceuticals issued its quarterly earnings data on Wednesday. The company reported EPS for the quarter, missing the Thomson Reuters consensus estimate of by $0.02, AnalystRatings.Net reports. Comment?
Keryx Biopharmaceuticals is expected to report earnings on Wednesday, May 8th. The whisper number is -$0.01, in-line with the analysts' estimate. Comment?
Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease , today announced its results for the first quarter ended March 31, 2013. Comment?
... data. Among the major movers were GlaxoSmithKline Plc (NYSE: GSK), AstraZeneca Plc (NYSE: AZN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has released free charting and technical research ... Comment?
The first four months of the trading year are now behind us, and the "big three" of U.S. market indices are all now up more than 10% year to date. Comment?
... look at the last year alone, there have been countless valuation-changing moves in biotechnology. Keryx Biopharmaceuticals ( KERX ) saw a two-day period where its stock more than doubled after reporting Phase 3 data. Sarepta Therapeutics ( SRPT ) ... Comment?
... rating in a report released on April 16. How Should Investors Trade SRPT Now? Find Out Here Keryx Biopharmaceuticals (NASDAQ:KERX) shares declined 2.53% to $8.10. The company, on Marc h 11, announced its results for the fourth quarter and year ended ... Comment?
Keryx Biopharmaceuticals traded at $ 8.32 in the last session, which is +0.29 . The stock has a Range of 8.06 - 8.64. The stock has a 52 week low and high of 1.34 - 9.98 respectively. Comment?
The online StockConsultant latest screen has found provider of drugs to for the treatment of cancer Keryx Biopharmaceuticals stock under a breakout watch above 8.81. KERX stock price is up 4.9% to 8.42 with 89.3% higher volume and is completing a string of two strong days higher. Comment?
Keryx Biopharmaceuticals shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. Comment?
... a leading patent attorney and former staff at the USPTO. The conference call centered around Keryx Biopharmaceuticals ( KERX ) and its lead drug candidate, Zerenex, which has come under scrutiny as questions have arisen about the drug's existing ... Comment?
Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
... with over 4.3 million shares that have exchanged hands, will ACAD continue to push? Stay tuned. Keryx Biopharmaceuticals (NASDAQ:KERX) is slowly trending north, trading at an intraday of $8.4998 (+5.85%) with over 3.6 million share exchanged, will ... Comment?